Method and reagent for inhibiting hepatitis B viral replication

• US 20040054156A1
• Filed: 01/15/2003
• Published: 03/18/2004
• Est. Priority Date: 05/14/1992
• Status: Abandoned Application

• Current Assignee: David Morrissey, James A. Mcswiggen, Kenneth Draper, Lawrence Blatt
• Original Assignee: David Morrissey, James A. Mcswiggen, Kenneth Draper, Lawrence Blatt
• Inventors: Draper, Kenneth, Morrissey, David, Blatt, Lawrence, McSwiggen, James A.
• Application Number:
  US10/342,902
• Publication Number:
  US 20040054156A1
• Time in Patent Office: Days
• US Class Current: 536/23.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: C07H 19/10 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 19/20 with the saccharide radical esterified by phosphoric or polyphosphoric acids
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 15/111 General methods applicable to biologically active non-coding nucleic acids
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 15/1131 against viruses
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/12 catalytic nucleic acids, e.g. ribozymes
• CPC Class Codes: C12N 2310/121 Hammerhead
• CPC Class Codes: C12N 2310/122 Hairpin
• CPC Class Codes: C12N 2310/13 Decoys
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/18 acting by a non-sequence specific mechanism other than C12N2310/16 or C12N2310/17
• CPC Class Codes: C12N 2310/315 : Phosphorothioates
• CPC Class Codes: C12N 2310/317 : with an inverted bond, e.g. a cap structure
• CPC Class Codes: C12N 2310/318 : where the PO2 is completely replaced, e.g. MMI or formacetal
• CPC Class Codes: C12N 2310/319 : linked by 2'-5' linkages, i.e. having a free 3'-position
• CPC Class Codes: C12N 2310/321 : 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 : 2'-R Modification
• CPC Class Codes: C12N 2310/332 : Abasic residue
• CPC Class Codes: C12N 2310/346 : having a combination of backbone and sugar modifications
• CPC Class Codes: C12N 2310/3519 : Fusion with another nucleic acid
• CPC Class Codes: C12N 2310/3521 : Methyl
• CPC Class Codes: C12N 2310/3523 : Allyl
• CPC Class Codes: C12N 2310/3531 : Hydrogen
• CPC Class Codes: C12N 2310/3533 : Halogen
• CPC Class Codes: C12N 2310/3535 : Nitrogen
• CPC Class Codes: C12N 2320/31 : Combination therapy
• CPC Class Codes: C12N 2320/51 : modulating the chemical stability, e.g. nuclease-resistance
• CPC Class Codes: C12N 2730/10122 : New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12P 19/30 : Nucleotides
• CPC Class Codes: C12P 19/305 : Pyrimidine nucleotides
• CPC Class Codes: C12Q 1/706 : for hepatitis
• CPC Class Codes: C12Y 207/07049 : RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
• CPC Class Codes: C12Y 301/03048 : Protein-tyrosine-phosphatase (3.1.3.48)

Abstract

The present invention relates to nucleic acid molecules, including antisense and enzymatic nucleic acid molecules, such as hammerhead ribozymes, DNAzymes, Inozymes, Zinzymes, Amberzymes, and G-cleaver ribozymes, which modulate the synthesis, expression and/or stability of an RNA encoding one or more protein components of Hepatitis B virus (HBV), and methods for their use alone or in combination with other therapies, such as 3TC® (Lamivudine) and Interferons are disclosed.

Claims

1. An enzymatic nucleic acid molecule that specifically cleaves RNA derived from hepatitis B virus (HBV), wherein said enzymatic nucleic acid molecule comprises one or more binding arms and wherein said enzymatic nucleic acid molecule does not require the presence of a 2′

-OH group within said enzymatic nucleic acid molecule for activity.

2. The enzymatic nucleic acid molecule of claim 1, wherein said binding arm(s) of said enzymatic nucleic acid molecule comprises between 12 and 100 nucleotides.

3. The enzymatic nucleic acid molecule of claim 1, wherein said binding arm(s) of said enzymatic nucleic acid molecule comprises between 14 and 24 bases.

4. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid is chemically synthesized.

5. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid comprises at least one 2′

-sugar modification.

6. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid comprises at least one nucleic acid base modification.

7. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid comprises at least one phosphate backbone modification.

8. A mammalian cell comprising the enzymatic nucleic acid molecule of claim 1.

9. The mammalian cell of claim 8, wherein said mammalian cell is a human cell.